Clinical Trials

240 enrolled

Clinical Stage I Gastric Cancer AJCC v8

NCT03653507 2026-04-17

GLOW

507 enrolled 65 charts 2 FDA

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT05152147 2026-04-17

HERIZON-GEA-01

920 enrolled

Phase 1 Active not recruiting

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT06544655 2026-04-17

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

213 enrolled

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT04661150 2026-04-16

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

42 enrolled 9 charts

Stomach Neoplasms

NCT03451370 2026-04-15

COBRA

Active not recruiting

121 enrolled

Elderly Metastatic Colorectal Cancer Patients

NCT03776487 2026-04-15

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

32 enrolled

Clinical Stage 0 Gastric Cancer AJCC v8

NCT04481204 2026-04-15

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

105 enrolled

Borderline Resectable Pancreatic Adenocarcinoma

NCT02912559 2026-04-14

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

712 enrolled 14 charts

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, DNA Repair-Deficiency Disorders

NCT00217737 2026-04-13

Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

2,431 enrolled 13 charts

Colonic Neoplasms

NCT02394834 2026-04-13

An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer

Active not recruiting

757 enrolled

Colorectal Neoplasms

NCT02997228 2026-04-13

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

120 enrolled

Phase 1 Active not recruiting

Colorectal Neoplasms

NCT03321643 2026-04-13

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

24 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05564403 2026-04-13

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

66 enrolled

Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT06417476 2026-04-13

Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer

66 enrolled

Rectal Neoplasms

NCT04745988 2026-04-09

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

43 enrolled

Stomach Neoplasms

NCT05945823 2026-04-09

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

53 enrolled

Phase 1/2 Active not recruiting

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT04542824 2026-04-08

EPCORE™ NHL-3

78 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04663347 2026-04-08

EPCORE™ NHL-2

Phase 1/2 Active not recruiting

543 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05083481 2026-04-08

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

226 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT06508658 2026-04-08

EPCORE DLBCL-4

379 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03764553 2026-04-07

LyRICX

320 enrolled

Esophageal Neoplasms

NCT04408638 2026-04-07

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

270 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03505320 2026-04-03

ILUSTRO

143 enrolled

Neoplasms, Stomach Neoplasms

NCT04245865 2026-04-03

Toco-CoR

83 enrolled

Colorectal Neoplasms

NCT05568095 2026-04-02

STAR-221

1,040 enrolled

Phase 1 Active not recruiting

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT05891171 2026-03-31

ARC-25

40 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05329766 2026-03-30

EDGE-Gastric

332 enrolled